Concepedia

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

Salomon Tendler, Mark Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G. Aly, Noura J. Choudhury, Adam Kesner, Assen Kirov, Audrey Mauguen, Marina K. Baine,

The Lancet Oncology · 2024 · 49 citations · 21 references

DOIFull text

Open access

Concepts

References

21

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Michael G. Stabin, Richard Sparks, Eric A. Crowe · PubMed · 2005 · 1.4K citations

, , +14

<i>Rb1</i> and <i>Trp53</i> cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

Sheng‐Yu Ku, Spencer R. Rosario, Yanqing Wang et al. · Science · 2017 · 1.1K citations

, , +17

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Rahul Aggarwal, Jiaoti Huang, Joshi J. Alumkal et al. · Journal of Clinical Oncology · 2018 · 812 citations

, , +17

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Laura R. Saunders, Alexander J. Bankovich, Wade Anderson et al. · Science Translational Medicine · 2015 · 578 citations

, , +17

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

Jonathan I. Epstein, Mahul B. Amin, Himisha Beltran et al. · The American Journal of Surgical Pathology · 2014 · 576 citations · Full text

, , +17